Articles tagged with Cancer Patients
A new study found that individuals with diabetes may have a higher risk of developing cancer before and immediately after a diabetes diagnosis. The study suggests that type 2 diabetes may increase the risk of several types of cancer, particularly shortly after diagnosis.
Researchers at H. Lee Moffitt Cancer Center discovered a novel way to control SETDB1 protein activity through monoubiquitination, which inhibits target gene expression and could lead to new cancer therapeutics. This breakthrough suggests E2 enzymes as attractive targets for cancer treatment.
A diagnosis of high cholesterol is associated with reduced mortality and improved survival in four common cancers: lung, breast, prostate, and bowel cancer. Statins are linked to lower risk of death, with significant reductions seen in all four types of cancer.
A recent study has discovered a strong link between genetic mutations and sensitivity to specific drugs in patient-derived cancer cell lines. The researchers found that these cell lines harbor most of the same genetic changes found in patients' tumors, making them useful models for identifying effective treatments.
A study led by Boston Children's Hospital researchers finds that the loss of let-7 microRNA family is central to neuroblastoma development. The study suggests strategies focused on restoring let-7 could provide a fresh, low-toxicity approach to treating this childhood cancer.
A genetic test that spots cancer-related DNA in blood can accurately predict colon cancer recurrence, according to a study of Australian patients. The 'liquid biopsy' detected DNA fragments in the blood of 20 patients with early-stage colon cancer, 11 of whom developed recurrences.
A phase II study evaluates the safety of palbociclib in African American patients, including those with benign ethnic neutropenia. The study aims to determine if these patients can safely use the drug, which was previously excluded due to risk of infection.
The research team will explore the biological and genetic underpinnings of breast cancer in African-American women, with a focus on identifying novel genes and gene pathways. The study aims to improve knowledge of breast cancer biology, particularly for this population.
A genetic test detecting tumor DNA in blood accurately predicts colon cancer recurrence in some patients. The test could help clinicians decide which patients need additional treatment after surgery, improving diagnostic approaches and potentially increasing survival rates.
A new study reveals that Argentine tango practice can significantly improve balance and reduce falls risk among cancer patients experiencing peripheral neuropathy. The dance intervention course reduced standing postural sway by 56% in just five weeks, providing a promising balance intervention for cancer survivors.
Researchers identified genetic mutations in immune system genes that may lead to synchronous colorectal cancer, a rare type of bowel tumor. The study found that these patients have inherited damaging mutations that can cause an inflammatory environment in the gut, increasing the frequency of independent cancer-initiating events.
The article introduces a new 'game plan' for oncologists to incorporate new therapies and approaches into clinical guidelines quickly. CancerLinQ, a web-based rapid-learning system, will provide point-of-care clinical decision support with the latest evidence-based recommendations.
MABp1 improves symptoms, reduces inflammation and increases clinical response rate by 76%, with a 3x longer survival time for responders. Excellent safety and tolerability were also observed.
The study projects that by 2040, there will be 26.1 million cancer survivors in the US, with 73% aged 65 or older. Increasing age increases the chance of comorbid conditions, and gaps exist between men and women in older age groups.
A phase III trial found that chemoradiotherapy after surgery for gastric cancer (GC) does not achieve better outcomes than post-operative chemotherapy. The study, which involved 788 patients, showed equivalent five-year survival rates of 40.8% in both treatment arms.
A new study reveals that only 8% of patients with large, apparently benign polyps have cancer, suggesting advanced endoscopic treatments like EMR and ESD as viable options. This finding could improve patient outcomes, reduce complications, and lower healthcare costs.
Researchers developed a novel method to identify likely cancer drivers among hundreds of genomic alterations. The technique uses tumor gene alterations to report on cancer progression, pinpointing GON4L as a potential driver and therapeutic target.
A Rice University lab developed a predictive model to treat leukemia patients, using a unique set of patient data. The top-performing models were able to predict patient response to therapy with an accuracy of close to 80 percent.
A study found that adults with acute leukemia had a significantly higher risk of death if they lived in certain North Carolina regions with limited healthcare resources. Researchers analyzed data from 2003 to 2009 and found that patients in these areas were more likely to die, even after controlling for other factors.
Researchers found that increasing doses of cisplatin were associated with increased hearing loss at most tested frequencies, and high blood pressure was also linked to hearing loss in these patients. Comprehensive hearing assessments are recommended for survivors given cisplatin-based chemotherapy.
Researchers at Johns Hopkins found an association between microbiome makeup and head and neck cancer. The study suggests that specific bacterial populations may be used to discriminate between patients with cancer and healthy individuals.
Researchers have identified a protein called GlyRS that contributes to higher mortality in breast cancer patients by launching cancer growth. The study suggests targeting this protein could lead to the development of new anti-cancer therapies.
A new treatment developed by UTSA researcher Matthew Gdovin can kill up to 95% of cancer cells in two hours using a single dose and a beam of light. The method involves injecting a chemical compound into the tumor and then exposing it to a beam of light, causing the cells to become acidic and commit suicide.
A study of patients who died at VA hospitals found that family-reported end-of-life care was significantly better for those with cancer or dementia than for those with other serious illnesses. Increasing access to palliative care may improve quality of end-of-life care for patients dying of heart, lung, and kidney diseases.
The study found that families reported better quality of end-of-life care for patients with cancer or dementia compared to those with end-stage renal disease (ESRD), cardiopulmonary failure, or frailty. Palliative care consultations, do-not-resuscitate orders, and setting of death were associated with improved quality of care.
Obese male mice produce female pups that are overweight and have delayed breast tissue development, linked to increased breast cancer risk. Researchers found epigenetic changes in miRNA signatures of dad's sperm and daughter's breast tissue
Researchers at Johns Hopkins Medicine report a link between cancer immunotherapy drugs and rheumatologic diseases, including inflammatory arthritis. The study highlights the need for awareness among patients and clinicians about potential side effects of these drugs.
A Yale-led study found that the EGFR cancer gene silences tumor suppressor genes in lung and glioblastoma brain cancers using a common mechanism. This discovery informs future research directions and may help determine how effective treatments will be against different EGFR mutations.
A landmark study has identified five new potential genes linked to bowel cancer, while also confirming the role of major existing genes in increasing risk. The research suggests that minor DNA variations play a significant role in inherited risk and environmental factors, with potential implications for prevention and treatment.
Researchers developed a new CAR T cell therapy that targets solid tumors using an antibody-carbohydrate combination. The therapy was shown to be effective in mouse models of pancreatic cancer, with increased survival rates and no damage to normal human cells.
Researchers at H. Lee Moffitt Cancer Center & Research Institute used a mathematical model to show that tumor cells on the edge and interior develop distinct characteristics, investing resources in survival or invasion, respectively.
Researchers have identified three primary molecular sub-groups of bladder cancer, with distinct characteristics and disease-developing patterns. The findings may enable more effective risk assessment and tailored treatment options for patients with superficial tumours.
Researchers identified a small-molecule inhibitor that disrupted the recruitment of Mastermind-like protein 1 to the Notch transcription complex, inhibiting cancer cell growth and supressing tumor growth in mouse xenograft studies. This discovery represents a new paradigm for Notch-based anticancer therapeutics.
A new fluorescent agent and imaging system guided surgeons in real-time to remove additional ovarian tumors that were not visible without fluorescence or could not be felt during surgery. This improved visualization allowed for the detection of an additional 29% of malignant lesions.
A novel CT-based calculation method, SULps, accurately measures lean body mass using computed tomography, leading to more precise PET imaging results. This improvement enables better staging of disease and therapy monitoring in cancer patients.
Scientists at Washington University School of Medicine identified over 850 DNA mutations linked to cancer that may be responsive to existing drugs. The study provides a list of mutations and associated drugs that could benefit patients, expanding the number of cancer treatments available.
Researchers found that blocking PRMT5 forces resistant brain-tumor cells into senescence, slowing or stopping tumor growth. This approach may offer a new treatment option for patients with glioblastoma.
A recent survey found that less than half of family physicians believe that lung cancer screening using low-dose computed tomography (LDCT) reduces lung cancer-related deaths. Despite the American Cancer Society's support for LDCT screening, many physicians are unsure about current recommendations.
Researchers at University of California - Davis Health found that patients with late-stage lung cancer who undergo surgery have better survival rates than those who don't. However, only 11% of these patients receive surgery, highlighting a need for improved access to care.
A new mutation in the ZBTB7A gene boosts energy metabolism in leukemia cells, promoting their growth and survival. This discovery offers a promising therapeutic target for treating acute myeloid leukemia (AML) patients.
Researchers develop a new method to analyze genetic sequences, known as SURVIV, which can predict cancer patients' survival times with greater accuracy. This technique may also enable doctors to target specific genetic sequences that could fight disease, according to the study published in Nature Communications.
A new breath test has been developed to identify lung cancer after surgery, using a simple, affordable process that analyzes carbonyl volatile organic compounds in exhaled breath. The test shows great potential for detecting lung cancer at any point, both as primary screening and post-surgery monitoring.
The Harold Alfond Foundation's charitable gift will support The Jackson Laboratory's efforts to enhance cancer diagnostics and treatment in Maine. JAX aims to provide precision cancer care using the latest genetic technologies to determine the best treatment for each patient.
Scientists identified 11 major groups of AML, each with unique genetic changes driving the disease. The study's findings improve diagnosis and treatment for young AML patients by predicting survival rates based on genetic complexity.
A study by Loyola Medicine found that mesothelioma surgery, specifically pleurectomy and decortication, improves quality of life in patients. The procedure can control fluid buildup, improve breathing, and reduce cancer pain, with benefits observed as early as one month after surgery.
A study published in JNCI found that patients treated at high-volume centers had statistically significant longer overall survival compared to those at low-volume centers. The difference was greater than 10% at two years, suggesting improved disease control and management of adverse effects.
Regular skin checks during PCP visits improve melanoma detection and treatment outcomes. Thinner melanomas detected through screening have a better prognosis than thicker ones.
Researchers from Scripps Research Institute have been awarded $1.3 million to optimize probes for a new cancer treatment approach. The study focuses on the retinoic acid receptor-related orphan receptors (ROR) gamma and molecules that bind to it, aiming to trigger immune cells to attack tumor cells.
Researchers analyzed data from Washington State hospital database and found no difference in cancer rates between patients who received rhBMP and those who did not. The study's findings suggest that additional follow-up is needed to rule out any longer-term increase in cancer risk.
A study found that nearly two-thirds of younger cancer patients with metastatic disease received hospitalization, emergency room visits, or chemotherapy in their last 30 days. Researchers call for earlier discussions on palliative care to improve quality of life.
Researchers from Thomas Jefferson University have identified a panel of microRNAs in blood samples that can predict patients at high risk of developing hepatocellular carcinoma, the most common type of liver cancer, in individuals infected with hepatitis B virus.
Preliminary results suggest that the selinexor combination regimen is active in relapsed and refractory multiple myeloma. Of 10 evaluable patients, two each achieved a very good partial response, a partial response, and a minimal response.
A Phase II clinical trial conducted by MD Anderson Cancer Center found that nivolumab significantly improves outcomes for patients with squamous cell carcinoma of the anal canal, with a control rate of 70%. The study enrolled 39 patients and demonstrated efficacy in both HIV-positive and non-HIV positive populations.
A clinical trial shows atezolizumab, a checkpoint inhibitor, is effective in treating advanced bladder cancer, shrinking tumors and stopping new growth. The drug was well-tolerated, with mild side effects, and half of patients responded within 15 weeks.
A clinical trial found that patients with tumors overexpressing DLL3 responded better to the experimental drug rovalpituzumab tesirine (Rova-T), achieving stabilization of disease and significant tumor reductions. The results suggest Rova-T may be a promising treatment option for advanced small cell lung cancer.
A Phase 3 clinical trial found that patients with high-risk neuroblastoma who received two autologous stem-cell transplants had higher event-free and overall survival rates compared to those who underwent a single transplant. The study also showed improved outcomes when immunotherapy was added to the treatment regimen.
A Phase I/II clinical trial found that nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of PD-L1 marker presence. The treatment was well-tolerated and showed a median survival of at least one year for 45.6% of patients.
Researchers at H. Lee Moffitt Cancer Center report a safe and effective treatment regimen for recurrent high-grade glioma brain tumors, with durable disease control in three patients. The combination of pembrolizumab, bevacizumab, and radiation therapy shows promise as a potential new approach to treating these patients.
A new pre-surgery technique using an expandable tube may make colostomy bags redundant for emergency bowel cancer patients. The study found that less than half of those who had their bowel unblocked needed a colostomy bag, while more than two-thirds required one after emergency surgery.
Researchers at UT Southwestern Medical Center discovered that between 14 to 25 percent of lung cancer patients also have immune disease, making them unsuitable for immunotherapy treatments. This finding raises critical questions about the effectiveness and toxicity of these treatments among patients with autoimmune diseases.